INTRODUCTION: X-linked myopathy with excessive autophagy (XMEA) is characterized by autophagic vacuoles with sarcolemmal features. Mutations in VMA21 result in insufficient lysosome acidification, causing progressive proximal weakness with onset before age 20 years and loss of ambulation by middle age. METHODS: We describe a patient with onset of slowly progressive proximal weakness of the lower limbs after age 50, who maintains ambulation with the assistance of a cane at age 71. RESULTS: Muscle biopsy at age 66 showed complex muscle fiber splitting, internalized capillaries, and vacuolar changes characteristic of autophagic vacuolar myopathy. Vacuoles stained positive for sarcolemmal proteins, LAMP2, and complement C5b-9. Ultrastructural evaluation further revealed basal lamina reduplication and extensive autophagosome extrusion. Sanger sequencing identified a known pathologic splice site mutation in VMA21 (c.164-7T>G). CONCLUSIONS: This case expands the clinical phenotype of XMEA and suggests VMA21 sequencing be considered in evaluating men with LAMP2-positive autophagic vacuolar myopathy.
INTRODUCTION:X-linked myopathy with excessive autophagy (XMEA) is characterized by autophagic vacuoles with sarcolemmal features. Mutations in VMA21 result in insufficient lysosome acidification, causing progressive proximal weakness with onset before age 20 years and loss of ambulation by middle age. METHODS: We describe a patient with onset of slowly progressive proximal weakness of the lower limbs after age 50, who maintains ambulation with the assistance of a cane at age 71. RESULTS: Muscle biopsy at age 66 showed complex muscle fiber splitting, internalized capillaries, and vacuolar changes characteristic of autophagic vacuolar myopathy. Vacuoles stained positive for sarcolemmal proteins, LAMP2, and complement C5b-9. Ultrastructural evaluation further revealed basal lamina reduplication and extensive autophagosome extrusion. Sanger sequencing identified a known pathologic splice site mutation in VMA21 (c.164-7T>G). CONCLUSIONS: This case expands the clinical phenotype of XMEA and suggests VMA21 sequencing be considered in evaluating men with LAMP2-positive autophagic vacuolar myopathy.
Authors: Y Tanaka; G Guhde; A Suter; E L Eskelinen; D Hartmann; R Lüllmann-Rauch; P M Janssen; J Blanz; K von Figura; P Saftig Journal: Nature Date: 2000-08-24 Impact factor: 49.962
Authors: B Chabrol; D Figarella-Branger; M Coquet; J Mancini; D Fontan; J M Pedespan; C Francannet; J Pouget; A M Beaufrère; J F Pellissier Journal: Neuromuscul Disord Date: 2001-05 Impact factor: 4.296
Authors: L Villard; V des Portes; N Levy; J P Louboutin; D Recan; M Coquet; B Chabrol; D Figarella-Branger; J Chelly; J F Pellissier; M Fontes Journal: Eur J Hum Genet Date: 2000-02 Impact factor: 4.246
Authors: K Sugie; A Yamamoto; K Murayama; S J Oh; M Takahashi; M Mora; J E Riggs; J Colomer; C Iturriaga; A Meloni; C Lamperti; S Saitoh; E Byrne; S DiMauro; I Nonaka; M Hirano; I Nishino Journal: Neurology Date: 2002-06-25 Impact factor: 9.910
Authors: H Kalimo; M L Savontaus; H Lang; L Paljärvi; V Sonninen; P B Dean; K Katevuo; A Salminen Journal: Ann Neurol Date: 1988-03 Impact factor: 10.422
Authors: Stephanie A Fernandes; Camila F Almeida; Lucas S Souza; Monize Lazar; Paula Onofre-Oliveira; Guilherme L Yamamoto; Letícia Nogueira; Letícia Y Tasaki; Rafaela R Cardoso; Rita C M Pavanello; Helga C A Silva; Merari F R Ferrari; Anne Bigot; Vincent Mouly; Mariz Vainzof Journal: Dis Model Mech Date: 2020-01-10 Impact factor: 5.758
Authors: Magda Cannata Serio; Laurie A Graham; Angel Ashikov; Tom H Stevens; Matias Simons; Dirk J Lefeber; Lars Elmann Larsen; Kimiyo Raymond; Sharita Timal; Gwenn Le Meur; Margret Ryan; Elzbieta Czarnowska; Jos C Jansen; Miao He; Can Ficicioglu; Pavel Pichurin; Linda Hasadsri; Berge Minassian; Alessandra Rugierri; Hannu Kalimo; W Alfredo Ríos-Ocampo; Christian Gilissen; Richard Rodenburg; Johan W Jonker; Adriaan G Holleboom; Eva Morava; Joris A Veltman; Piotr Socha Journal: Hepatology Date: 2020-12 Impact factor: 17.298